A new trading day began on November 20, 2023, with TransCode Therapeutics Inc (NASDAQ: RNAZ) stock priced at $0.262, down -12.60% from the previous day of trading. During the day, the shares moved up to $0.2634 and dropped to $0.1494 before settling in for the closing price of $0.26. RNAZ’s price has ranged from $0.25 to $23.40 over the past 52 weeks.
Meanwhile, its annual earnings per share averaged 79.37%. With a float of $19.67 million, this company’s outstanding shares have now reached $20.10 million.
Considering the fact that the conglomerate employs 19 people, you should pay attention to its efficiency factor.
TransCode Therapeutics Inc (RNAZ) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of TransCode Therapeutics Inc is 2.13%, while institutional ownership is 2.63%. The most recent insider transaction that took place on Sep 28, was worth 49,980. In this transaction Chief Executive Officer of this company bought 98,000 shares at a rate of $0.51, taking the stock ownership to the 180,262 shares. Before that another transaction happened on Sep 28, when Company’s Chief Financial Officer bought 49,350 for $0.51, making the entire transaction worth $25,168. This insider now owns 56,318 shares in total.
TransCode Therapeutics Inc (RNAZ) Earnings and Forecasts
In its latest quarterly report, released on 9/29/2023, the company reported earnings of -$1.68 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). This company achieved a return on equity of -148.57. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 79.37% per share during the next fiscal year.
TransCode Therapeutics Inc (NASDAQ: RNAZ) Trading Performance Indicators
Here are TransCode Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -19.57, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach -0.63 in one year’s time.
Technical Analysis of TransCode Therapeutics Inc (RNAZ)
Compared to the last year’s volume of 1.93 million, its volume of 1.72 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 10.07%. Additionally, its Average True Range was 0.08.
During the past 100 days, TransCode Therapeutics Inc’s (RNAZ) raw stochastic average was set at 2.61%, which indicates a significant decrease from 23.68% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 89.36% in the past 14 days, which was lower than the 324.45% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5012, while its 200-day Moving Average is $3.9254. Nevertheless, the first resistance level for the watch stands at $0.2785 in the near term. At $0.3279, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.3925. If the price goes on to break the first support level at $0.1645, it is likely to go to the next support level at $0.0999. Should the price break the second support level, the third support level stands at $0.0505.
TransCode Therapeutics Inc (NASDAQ: RNAZ) Key Stats
With a market capitalization of 4.60 million, the company has a total of 2,026K Shares Outstanding. Currently, annual sales are 0 K while annual income is -17,560 K. The company’s previous quarter sales were 0 K while its latest quarter income was -4,340 K.